Elagolix, also known as Orilissa, is a prescription medication that is mainly used to treat endometriosis. It is important for patients to understand information about the price, drug interactions, and pharmacokinetics of the drug before using it.
The price of Elagolix Sodium Tablets
The price of Elagolix Sodium Tablets varies by region and version. Taking the Hong Kong version of the original drug as an example, it has two specifications: 150mg*28 tablets and 200mg*56 tablets.
Price differences
It is important to note that drug prices may vary depending on factors such as region, pharmacy, purchasing channel, etc. When purchasing, patients should choose formal channels and consult a doctor or pharmacist.
Medicare & Reimbursement
In addition, patients should also be aware of the reimbursement status of Elagolix Sodium Tablets under the Medicare Policy. In some regions, the drug may have been included in the medical insurance list, and patients can enjoy a certain reimbursement rate, thereby reducing the financial burden.
Now that we know the price of Elagolix Sodium Alpha Tablets, let's take a look at its drug interactions.
Drug-drug interactions of Elagolix sodium
There may be interactions between Elagolix sodium and other drugs that can affect the efficacy of the drug or increase the risk of adverse effects.
Potential effects of Elagolix sodium on other medications
Co-administration with a weak to moderate inducer of cytochrome P450 (CYP) 3A may reduce plasma concentrations of CYP3A substrate drugs; Co-administration with a weak inhibitor of CYP2C19 may increase the plasma concentration of the CYP2C19 substrate drug; Co-administration with an efflux transporter P-glycoprotein (P-gp) inhibitor may increase plasma concentrations of the drug that is a substrate for P-gp.
Potential effects of other drugs on Elagolix sodium
Sodium Elagolix is a substrate for CYP3A, P-gp, and OATP1B1. Strong CYP3A inhibitors do not recommend the combination of Elagolix 200mg twice a day in combination with a strong CYP3A inhibitor for more than 1month. The duration of concomitant use of Elagolix sodium 150mg once a day and a strong CYP3A inhibitor was limited to 6months.
Administration of sodium Elagolix in combination with a potent CYP3A inducer may reduce plasma concentrations of sodium Elagolix and may result in a decrease in the therapeutic efficacy of nalgolix sodium.
It is not recommended to use Elagolix sodium 200mg twice a day in combination with rifampicin. The combination of Elagolix sodium 150mg once a day and rifampicin was limited to 6months. The effect of concomitant use of P-gp inhibitors or inducers on the pharmacokinetics of Elagolix sodium is unknown. OATP1B1 inhibitors known or expected to significantly increase plasma concentrations of Elagolix sodium are contraindicated due to increased risk of Cerragolina-related adverse effects.
Let's take a look at the pharmacokinetics of sodium evil, which helps us better understand the absorption, distribution, metabolism and excretion of the drug in the body.
Pharmacokinetics of Elagolix sodium
The main metabolic pathway of sodium Elagolix is hepatic metabolism, and the terminal elimination half-life is 4-6 hours.
Absorption and distribution
After oral administration, sodium Elagolix is absorbed through the gastrointestinal tract into the blood circulation, and then distributed to all tissues throughout the body. Its specific absorption and distribution may vary from individual to individual.
Metabolism and excretion
Elagolix sodium is mainly metabolized in the liver, and the specific type and amount of metabolites may vary from individual to individual. The metabolized products are excreted from the body through the kidneys or bile.
When using Elagolix Sodium Alpha Tablets, patients should follow the doctor's advice and guidance, take the drug on time and in accordance with the amount, should pay close attention to the physical reaction, if there is any discomfort or doubt, should seek medical consultation in time, and patients should also avoid adjusting the dosage of the drug or stopping the drug by themselves, so as not to affect the efficacy of the drug or increase the risk of adverse reactions.
